Incorrect password
evipedia.ai Suggest Edit

Oleoylethanolamide for Health & Longevity

Evidence Review created on 04/27/2026 using AI4L / Opus 4.7

Also known as: OEA, N-oleoylethanolamide, N-oleoylethanolamine, Oleic Acid Ethanolamide, Oleamide MEA

Motivation

Oleoylethanolamide is a fat-derived signaling molecule that the small intestine releases after a meal containing oleic acid, the dominant fatty acid in olive oil. Inside the gut wall it activates a fat-burning nuclear receptor and stimulates vagal sensory nerves, which together translate “I have absorbed enough fat” into reduced hunger, increased fat burning, and lower post-meal inflammation. Supplemental oleoylethanolamide essentially boosts a signal the body already produces and is sold as a stand-alone capsule.

Interest in oleoylethanolamide has accelerated as recent pooled clinical analyses reported consistent reductions in body weight, waist circumference, fasting glucose, triglycerides, and inflammatory markers in overweight and metabolically compromised adults. The molecule is also one of four metabolites produced during prolonged human fasting that extend lifespan in nematode models, which has attracted attention from the longevity field, and a new wave of human trials in metabolic and gut-microbiome contexts is underway. Commercial availability expanded after a major ingredient form received regulatory acknowledgment in the United States as a New Dietary Ingredient.

This review examines the mechanistic basis, clinical evidence, side-effect profile, sourcing, dosing protocols, and monitoring strategy relevant to adults considering oleoylethanolamide as a metabolic and longevity intervention.

Benefits - Risks - Protocol - Conclusion

A curated set of resources offering accessible, substantive overviews of oleoylethanolamide’s biology, mechanisms, and clinical evidence.

  • Beyond CBD: Four Plants Support The Endocannabinoid System - Paul Johnson

    Long-form Life Extension Magazine article covering oleoylethanolamide as one of four bioactive compounds that influence endocannabinoid-system tone, with practical discussion of its roles in appetite control, post-meal inflammation, and metabolic regulation.

  • Oleic acid-derived oleoylethanolamide: A nutritional science perspective - Bowen et al., 2017

    Comprehensive narrative review in Progress in Lipid Research synthesizing how dietary oleic acid is converted to oleoylethanolamide in intestinal membranes, the resulting PPAR-alpha (peroxisome proliferator-activated receptor alpha, a nuclear transcription factor that drives fatty-acid oxidation and energy-utilization genes)-mediated effects on lipid oxidation and satiety, and the implications of high-oleic-acid diets for body composition.

  • Oleoylethanolamide: A fat ally in the fight against obesity - Brown et al., 2017

    Accessible narrative review describing oleoylethanolamide’s dual action as a peripheral satiety signal and a modulator of dopamine-driven food-reward circuits, with framing of why it emerged as a safer alternative to discontinued cannabinoid-based weight-loss drugs.

  • Oleoylethanolamide: A Novel Potential Pharmacological Alternative to Cannabinoid Antagonists for the Control of Appetite - Romano et al., 2014

    Comparative review and head-to-head behavioral study contrasting oleoylethanolamide with rimonabant (the withdrawn CB1 antagonist), demonstrating that oleoylethanolamide induces satiety without the aversive behavioral signals associated with cannabinoid blockade.

No directly relevant content from Peter Attia, Andrew Huberman, Rhonda Patrick, or Chris Kresser could be identified despite repeated searches across each platform. Only 4 high-quality eligible items were found. The non-systematic-review literature on oleoylethanolamide is dominated by primary clinical trials (which belong in other sections) and supplement-marketing pages (which do not qualify as substantive overviews). The Life Extension Magazine article and the three narrative reviews above represent the strongest accessible material currently available.

Grokipedia

  • Oleoylethanolamide

    Detailed Grokipedia article covering oleoylethanolamide’s biosynthesis from the membrane lipid N-oleoyl-phosphatidylethanolamine, its high-affinity PPAR-alpha agonism (EC50 ~120 nM), additional signaling through TRPV1 and GPR119, and the magnitude of body-weight effects observed in chronic rodent dosing studies.

Examine

Examine.com does not currently publish a primary, dedicated supplement page for oleoylethanolamide; only a research-summaries filter view exists, which does not qualify as a primary article.

ConsumerLab

ConsumerLab does not currently publish a dedicated review or third-party product test report for oleoylethanolamide supplements.

Systematic Reviews

A summary of systematic reviews and meta-analyses evaluating oleoylethanolamide supplementation, identified by a real-time PubMed search.

A potential structural-bias caveat applies across this evidence base: a substantial share of the underlying primary RCTs (randomized controlled trials, the highest-quality clinical study design for testing interventions) and several of the qualitative systematic reviews come from a single research cluster at Tabriz University of Medical Sciences in Iran (Tutunchi, Ostadrahimi, Payahoo, and colleagues), whose ongoing investment in oleoylethanolamide programs creates an incentive to publish positive findings. The 2025 meta-analyses by Bahari et al. and Eslahi et al. partially mitigate this by aggregating across groups, but until replication outside this cluster broadens, the geographic and institutional concentration of the source data should be considered when weighing effect sizes.

Mechanism of Action

Oleoylethanolamide is an N-acylethanolamine (a fatty-acid-derived signaling lipid built on an ethanolamine backbone) derived endogenously from the membrane phospholipid N-oleoyl-phosphatidylethanolamine (NOPE, a precursor lipid stored in cell membranes) in enterocytes (cells lining the small intestine) in response to dietary fat. Its biological effects arise from convergent action on several targets:

  • PPAR-alpha activation: Oleoylethanolamide is a high-affinity agonist of PPAR-alpha, with an EC50 (half-maximal effective concentration, the dose at which half the maximum effect is reached) of approximately 120 nM. PPAR-alpha activation upregulates carnitine palmitoyltransferase 1 and other fat-burning enzymes, suppresses appetite-relevant gene programs, and tempers inflammation. This pathway accounts for most of the metabolic and weight effects reported in human trials.

  • Vagal satiety signaling: After a fatty meal, oleoylethanolamide produced in proximal small-intestine enterocytes activates sensory fibers of the vagus nerve. The signal is relayed through the nucleus tractus solitarius to hypothalamic feeding centers, ending the meal. Vagotomy abolishes the anorexigenic effect in animal models, confirming the centrality of this pathway.

  • GPR119 activation: Oleoylethanolamide binds GPR119 (G protein-coupled receptor 119, expressed on intestinal L-cells and pancreatic beta-cells), stimulating release of GLP-1 (glucagon-like peptide-1, an incretin that enhances insulin secretion and slows gastric emptying) and contributing to glucose homeostasis. GPR119’s EC50 for oleoylethanolamide (~3 µM) is higher than PPAR-alpha’s, so GPR119 effects are likely most relevant at supraphysiological postprandial concentrations or with supplementation.

  • TRPV1 modulation: At higher concentrations oleoylethanolamide also activates TRPV1 (transient receptor potential vanilloid 1, the capsaicin receptor), which contributes to vagal-afferent excitation and short-term food-intake reduction.

  • Anti-inflammatory action: Through PPAR-alpha and partially independent mechanisms, oleoylethanolamide suppresses NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells, a master transcription factor for inflammatory genes), lowers TNF-alpha and CRP (C-reactive protein, a blood marker of systemic inflammation), and elevates IL-10 (interleukin-10, an anti-inflammatory cytokine).

  • Antioxidant effects: Oleoylethanolamide raises total antioxidant capacity and reduces malondialdehyde, indicating reduced lipid peroxidation, likely downstream of PPAR-alpha-driven gene expression changes.

  • Reward and dopaminergic modulation: Oleoylethanolamide enhances dopamine signaling in the dorsal striatum and modulates the hedonic component of food intake, distinguishing it from purely homeostatic satiety mediators.

  • Endogenous lipid network: Oleoylethanolamide is degraded by FAAH (fatty acid amide hydrolase, the primary enzyme that hydrolyzes N-acylethanolamines) and NAAA (N-acylethanolamine acid amidase, a secondary degradative enzyme that breaks down N-acylethanolamines, especially within lysosomes) into oleic acid and ethanolamine. It shares biosynthetic and degradative machinery with anandamide and palmitoylethanolamide; competitive interactions can shift relative tone within this network.

Pharmacological properties: A formal pharmacokinetic profile in humans is not yet published; oleoylethanolamide is rapidly degraded by FAAH/NAAA, with endogenous turnover on the order of minutes to hours. Available human pharmacokinetic data (Rhodes et al., 2024) and rodent studies suggest a plasma half-life on the order of approximately 1–3 hours, with oral administration producing measurable plasma elevations within 1–4 hours. Selectivity is highest for PPAR-alpha (EC50 ~120 nM), with secondary activity at GPR119 (~3 µM) and TRPV1 at higher concentrations. Tissue distribution is broadest in intestine, liver, adipose, and brain. Metabolism is enzymatic via amide hydrolysis rather than hepatic CYP (cytochrome P450, the major drug-metabolizing enzyme family) pathways, which limits cytochrome-mediated drug interactions.

⚠️ Where competing mechanistic explanations exist, both views are presented: while PPAR-alpha is widely accepted as the primary mediator of chronic effects (body weight, lipids, inflammation), some authors emphasize that acute satiety in physiological postprandial conditions cannot be fully explained by PPAR-alpha alone (whose EC50 is higher than fasting plasma OEA but lower than postprandial intestinal concentrations) and assign meaningful roles to GPR119, TRPV1, and dopaminergic effects. Both perspectives are consistent with the current evidence base.

Historical Context & Evolution

Oleoylethanolamide was first identified as a bioactive lipid in the late 1990s, but the pivotal moment came in 2001, when Daniele Piomelli and colleagues at the University of California, Irvine published evidence that oleoylethanolamide is produced in the small intestine in response to dietary fat and reduces feeding through PPAR-alpha activation. This positioned the molecule as a key mediator of the gut-brain axis for fat sensing.

The discovery landed in the midst of major upheaval in obesity pharmacology. The CB1 cannabinoid antagonist rimonabant was approved in Europe in 2006 for obesity and withdrawn in 2008 because of severe psychiatric side effects, including depression and suicidality. Oleoylethanolamide offered an alternative pharmacological logic: modulating satiety through PPAR-alpha and vagal afferents rather than through cannabinoid-receptor blockade, sidestepping the central-nervous-system risks that doomed rimonabant. The 2014 Romano comparative behavioral study made this contrast explicit.

Translational interest grew through the 2010s as rodent studies repeatedly confirmed anti-obesity, anti-inflammatory, and neuroprotective signals. A commercial milestone came in 2015, when NutriForward LLC received FDA acknowledgment of “no objection” for RiduZone, a 90% oleoylethanolamide ingredient, as a New Dietary Ingredient — the first such acknowledgment for an oleoylethanolamide-based supplement.

Human RCTs began appearing in larger numbers from 2018 onward, led primarily by groups at Tabriz University of Medical Sciences in Iran (Tutunchi, Ostadrahimi, Payahoo, and colleagues) studying overweight, NAFLD (non-alcoholic fatty liver disease), and PCOS (polycystic ovary syndrome) populations. By 2025, accumulation of approximately 10–13 RCTs enabled two independent meta-analyses (Bahari et al.; Eslahi et al.), marking the transition from preclinical curiosity to a supplement with quantifiable clinical effects. Parallel work by Rhodes and Zivkovic at UC Davis identified oleoylethanolamide as one of four bioactive metabolites that rise during prolonged human fasting and extend nematode lifespan, opening a longevity-research framing for the molecule.

Expected Benefits

Medium 🟩 🟩

Reduction in Body Weight, Waist Circumference, and Fat Mass

Two independent 2025 meta-analyses converge on the conclusion that oleoylethanolamide supplementation modestly but consistently lowers body weight, BMI (body mass index), waist circumference, fat mass, and body-fat percentage relative to placebo. The Bahari et al. meta-analysis (10 RCTs) and the Eslahi et al. meta-analysis (13 RCTs) used overlapping but non-identical trial pools, strengthening confidence. The mechanistic basis is dual: appetite suppression through vagal and PPAR-alpha pathways, plus enhanced fatty-acid oxidation. The average participant in these trials was overweight or obese; magnitudes in metabolically healthy lean adults are unknown.

Magnitude: Pooled WMD of -2.15 cm for waist circumference; significant standard mean differences for body weight, BMI, fat mass, and body-fat percentage across both 2025 meta-analyses.

Improvement of Glycemic Control

Both 2025 meta-analyses report significant reductions in fasting glucose, fasting insulin, and HOMA-IR (Homeostatic Model Assessment for Insulin Resistance, a measure of insulin sensitivity) after oleoylethanolamide supplementation. Mechanistically, this reflects GPR119-mediated GLP-1 release, PPAR-alpha-driven improvements in hepatic and muscle insulin sensitivity, and the indirect effect of weight reduction. HbA1c, a longer-term glycemic measure, did not improve significantly in the Bahari et al. pool, suggesting the effect is detectable on short-term but not long-term glycemic markers in current trial durations.

Magnitude: WMD of -5.84 mg/dl for fasting glucose and -3.26 microU/ml for fasting insulin (Eslahi et al., 2025).

Reduction in Inflammatory and Oxidative Stress Markers ⚠️ Conflicted

Both meta-analyses report significant reductions in CRP and TNF-alpha and increases in total antioxidant capacity, with reductions in malondialdehyde. The IL-6 result is conflicted: Eslahi et al. (2025) reports a significant decrease, while Bahari et al. (2025) does not. The 2025 MAFLD network meta-analysis (Yang et al.) ranked oleoylethanolamide among the strongest interventions tested for boosting antioxidant enzyme activity. Effects appear largest in inflamed, metabolically compromised populations.

Magnitude: WMD of -2.44 pg/ml for TNF-alpha; WMD of +0.43 mg/dl for total antioxidant capacity (Eslahi et al., 2025).

Low 🟩

Triglyceride Reduction

Both 2025 meta-analyses report a significant decrease in triglycerides with oleoylethanolamide supplementation, while neither found significant effects on total cholesterol, LDL-C, or HDL-C. An RCT in NAFLD patients by Tutunchi et al. (2020) on atherogenic indices supports a meaningful triglyceride-mobilizing effect at 250 mg/day. The selectivity for triglycerides over other lipid fractions aligns with the PPAR-alpha mechanism, which preferentially mobilizes triglyceride-rich pathways.

Magnitude: WMD of -17.73 mg/dl for triglycerides (Eslahi et al., 2025).

Improved Liver Health Markers in Fatty Liver Disease

A series of RCTs by Tutunchi et al. in obese NAFLD patients (12-week intervention) found that oleoylethanolamide combined with a calorie-restricted diet significantly reduced hepatic fibrosis scores, atherogenic lipid ratios, NF-κB and IL-6 gene expression, and ALT (alanine aminotransferase, an enzyme that rises with liver-cell damage) and AST (aspartate aminotransferase, another liver enzyme), while elevating serum NRG4 (neuregulin 4, a hepatoprotective adipokine) and SIRT1 (sirtuin 1, a longevity-associated deacetylase enzyme), AMPK (AMP-activated protein kinase, a cellular energy sensor that promotes fat burning), and PGC-1α (a master regulator of mitochondrial biogenesis) gene expression (Tutunchi et al., 2023). The findings come predominantly from a single research group and require independent replication in larger populations.

Magnitude: Significant reductions in ALT and AST; SIRT1, AMPK, and PGC-1α mRNA upregulation versus placebo (Tutunchi et al., 2023).

Improved Glycemic and Inflammatory Markers in PCOS

Shivyari et al. (2024), a 90-participant RCT in women with polycystic ovary syndrome, reported that 125 mg/day of oleoylethanolamide for 8 weeks significantly improved fasting glucose, insulin resistance, MDA (malondialdehyde, a marker of oxidative stress), CRP, TNF-alpha, and anti-Müllerian hormone, while increasing total antioxidant capacity. This is the largest single PCOS-focused trial to date but has not yet been replicated.

Magnitude: Significant improvements across glycemic, oxidative-stress, and inflammatory parameters versus placebo (Shivyari et al., 2024).

Mood Improvement and Fatigue Reduction in Symptomatic Populations

The Abdullah et al. (2026) 15-week RCT in 52 veterans with Gulf War Illness reported significant reductions in fatigue (Multidimensional Fatigue Inventory) and total mood disturbance (Profile of Mood States) with 200 mg of oleoylethanolamide twice daily, plus improvements in self-reported energy, emotional well-being, and social functioning. Pain and cognitive measures did not change. As an exploratory single-site trial in a specific clinical population, the result is provisional.

Magnitude: Statistically significant changes on MFI-20 fatigue and POMS total mood scores at 10 and 15 weeks (Abdullah et al., 2026).

Speculative 🟨

Longevity-Aligned Fasting-Mimetic Effects

Rhodes et al. (2023) identified oleoylethanolamide as one of four metabolites that rise during 36-hour human fasting and can replicate fasting’s anti-inflammatory effects in human macrophages and extend median lifespan in Caenorhabditis elegans by up to 96% in combination. Rhodes et al. (2024) showed that oral co-supplementation with spermidine, nicotinamide, palmitoylethanolamide, and oleoylethanolamide produces dose-dependent plasma elevations and anti-inflammatory effects in healthy young men. Direct human longevity outcomes remain untested, and effects in invertebrates do not transfer reliably to humans, so this signal is mechanistic and indirect at present.

Neuroprotection and Stroke Recovery Adjunct

Sabahi et al. (2022), a 60-patient RCT in acute ischemic stroke, reported that oleoylethanolamide (300 mg/day or 600 mg/day, 3-day add-on to standard care) improved short-term inflammatory, oxidative-stress, and biochemical markers. Preclinical work shows oleoylethanolamide promotes microglial M2 polarization (an anti-inflammatory activation state) and limits neuronal injury through PPAR-alpha. Direct evidence for neuroprotective benefit from oral supplementation in healthy humans is absent.

Gut Microbiome Optimization

Payahoo et al. (2019), an RCT of 30 obese adults, found that 8 weeks of oleoylethanolamide significantly increased the abundance of Akkermansia muciniphila, a gut bacterium associated with improved metabolic health and intestinal-barrier integrity. The clinical significance of this microbiome shift for long-term outcomes in healthy adults remains untested.

Benefit-Modifying Factors

  • Genetic polymorphisms: Variants in the PPARA gene (encoding PPAR-alpha) may modulate transcriptional response to oleoylethanolamide; carriers of the L162V variant have reduced PPAR-alpha activity and could plausibly experience smaller effects, though this has not been clinically tested. Polymorphisms in FAAH (the primary degradative enzyme of oleoylethanolamide) influence endogenous baseline tone; the C385A variant produces a less stable enzyme and higher endogenous N-acylethanolamine levels, potentially shrinking the incremental benefit of supplementation. No pharmacogenomic dosing data exist.

  • Baseline biomarker levels: Adults with elevated CRP, TNF-alpha, fasting glucose, insulin, HOMA-IR, triglycerides, or central adiposity are likely to experience the largest absolute changes, mirroring the populations enrolled in the meta-analyzed trials. Metabolically healthy adults with already-low markers should expect minimal measurable shifts in lab values.

  • Sex-based differences: Trial populations are roughly balanced across sexes; female-only PCOS (Shivyari et al., 2024) and dysmenorrhea trials report robust effects, and the Gulf War Illness trial was 94% male. Sex-stratified analyses of metabolic outcomes have not been published, and acute endocannabinoid-system responses to cannabidiol show sex-specific OEA changes (Abboud et al., 2026), suggesting underlying sex-modulated tone that has not been fully characterized.

  • Pre-existing health conditions: Effect sizes are largest in adults with overweight, NAFLD/MAFLD, metabolic syndrome, or PCOS. Lean, metabolically healthy adults are underrepresented in the trial pool.

  • Age-related considerations: Trials predominantly enrolled adults aged 20–60. The Gulf War Illness trial extended to a mean age of 59 ± 5. Older adults (>65) with sarcopenia or reduced lean mass have not been formally studied; age-related decline in intestinal fat sensing and endogenous oleoylethanolamide synthesis could in principle make supplementation more impactful but might also increase the relative risk of unwanted weight loss.

  • Diet composition: A diet low in oleic acid (e.g., low olive oil intake, low monounsaturated fat) is associated with lower endogenous oleoylethanolamide tone; such individuals may experience proportionally larger benefits from supplementation, while adults eating a Mediterranean-style diet may see smaller incremental effects.

Potential Risks & Side Effects

Low 🟥

Mild Gastrointestinal Discomfort

Across published RCTs, the most commonly reported adverse effects are nausea, dyspepsia, mild bloating, and altered bowel habits. These are generally transient, mild, and often comparable to placebo rates. The Abdullah et al. (2026) Gulf War Illness trial explicitly reported no serious adverse events; the 2025 meta-analyses identified no safety signals beyond mild gastrointestinal complaints. Animal toxicity studies show no organ pathology even at very high doses (4,000 mg/kg in rodents).

Magnitude: Incidence comparable to placebo across published RCTs; no excess rate reported in the 2025 meta-analyses.

Headache

Headache has been recorded as an occasional event in oleoylethanolamide trials, typically at rates comparable to placebo. The proposed mechanism is unclear; possibilities include transient changes in cerebral perfusion related to PPAR-alpha-driven lipid mobilization or unrelated nocebo effects. The evidence basis is adverse-event tabulations from the published RCTs underpinning the 2025 meta-analyses; no signal of severity or persistence has been reported, and incidence does not separate from placebo. Reversibility appears complete on discontinuation.

Magnitude: Incidence does not separate from placebo in available trial adverse-event tabulations.

Speculative 🟨

Sleep Disturbance

A subset of users report mild difficulty initiating sleep when oleoylethanolamide is dosed late in the day. The proposed mechanism is enhanced dopaminergic signaling in the dorsal striatum and increased fatty-acid oxidation, both of which could plausibly raise evening alertness and core energy-metabolism activity. The evidence basis is anecdotal user reports rather than systematic trial assessment; no controlled study has formally measured sleep architecture under oleoylethanolamide supplementation. The effect appears dose-timing dependent and resolves with morning-only or earlier dosing.

Unintended Weight Loss in Lean Individuals

Because oleoylethanolamide reliably suppresses appetite in overweight populations, lean or already-underweight adults may experience unwanted reductions in caloric intake or body mass. No RCT has specifically enrolled normal-weight or underweight participants to evaluate this risk, so the magnitude is unknown.

Endocannabinoid-Network Perturbation

Oleoylethanolamide shares biosynthetic precursors and degradative enzymes (FAAH, NAAA) with anandamide and palmitoylethanolamide, and competitive substrate dynamics could in principle shift relative endocannabinoid tone with chronic high-dose supplementation. The long-term consequences for mood, pain perception, and reward processing are not characterized.

Sex-Specific Endocannabinoid Modulation

Acute exposure to cannabidiol produces sex-specific changes in plasma oleoylethanolamide (Abboud et al., 2026). Whether chronic supplementation interacts with hormonal cycles, oral contraceptives, or perimenopausal endocannabinoid shifts is unstudied.

Hypoglycemia Risk in Combination with Antidiabetic Therapy

While oleoylethanolamide alone has not produced clinical hypoglycemia in trials, its glucose-lowering effect could in principle add to that of insulin secretagogues, insulin, or GLP-1 receptor agonists. No human cases have been formally reported.

Risk-Modifying Factors

  • Genetic polymorphisms: FAAH C385A variant carriers (≈20% of populations of European descent) have reduced FAAH activity and slower oleoylethanolamide clearance; they may experience prolonged effects from a given dose, including any side effects. PPARA variants altering receptor sensitivity could modify both efficacy and tolerability.

  • Baseline biomarker levels: Adults with low body weight, low body-fat percentage, or low baseline appetite may be more susceptible to unwanted weight loss. Adults with already-low CRP and TNF-alpha will see less inflammatory benefit and bear all the same risks.

  • Sex-based differences: No systematic sex-specific safety differences have emerged in published trials, but plasma N-acylethanolamine responses differ by sex in pharmacokinetic studies, indicating that women and men may not metabolize supplemental oleoylethanolamide identically.

  • Pre-existing health conditions: Adults with active or historical eating disorders should not use an appetite-suppressing supplement without specialist supervision. Severe hepatic impairment (Child-Pugh Class C) may slow FAAH/NAAA-mediated clearance, prolonging exposure. Severe renal impairment (eGFR <30 ml/min/1.73 m²) has not been studied. Pregnant or breastfeeding adults have no human safety data.

  • Age-related considerations: Older adults (>65) with reduced lean mass should monitor for unintended weight loss. The oldest population in published trials had a mean age near 60.

Key Interactions & Contraindications

  • GLP-1 receptor agonists (e.g., semaglutide, liraglutide, tirzepatide): Oleoylethanolamide stimulates endogenous GLP-1 release through GPR119. Co-administration may produce additive appetite suppression, slowed gastric emptying, nausea, and excessive caloric restriction. Severity: caution; consider lower starting doses and monitor for tolerability.

  • Insulin secretagogues (sulfonylureas: glyburide, glipizide, glimepiride; meglitinides: repaglinide, nateglinide) and insulin: Oleoylethanolamide lowers fasting glucose and insulin and improves insulin sensitivity. Combining with hypoglycemic drugs may increase risk of clinically significant hypoglycemia. Severity: caution; mitigation: more frequent self-monitoring of blood glucose during the first 4 weeks; clinician review for possible dose reduction.

  • Other PPAR-alpha agonists (fibrates: fenofibrate, gemfibrozil): Pharmacodynamic overlap could amplify lipid-modifying effects but is unlikely to be clinically problematic; theoretical additive effect on hepatic enzyme upregulation. Severity: caution; monitor liver enzymes if combined.

  • Investigational FAAH inhibitors (e.g., PF-04457845): These drugs reduce oleoylethanolamide degradation and would amplify both effects and side effects of supplementation. Severity: avoid concurrent use outside research settings.

  • Cannabinoids and cannabidiol: Cannabidiol modulates plasma oleoylethanolamide and palmitoylethanolamide through competitive FAAH substrate dynamics; chronic combined use may shift the balance of endocannabinoid-network signaling. Severity: monitor; effect is bidirectional and not associated with documented harm.

  • Over-the-counter medications: No clinically significant interactions with NSAIDs (non-steroidal anti-inflammatory drugs: ibuprofen, naproxen), acetaminophen, antihistamines, or proton-pump inhibitors are documented or mechanistically predicted. Oleoylethanolamide is metabolized by amide hydrolases rather than CYP3A4 (cytochrome P450 3A4, the most prolific drug-metabolizing enzyme) or other CYP enzymes, sharply limiting CYP-mediated interactions.

  • Supplements with additive appetite-suppressing effects: Combining with caffeine, synephrine, capsaicin/capsinoids, glucomannan, or 5-HTP (5-hydroxytryptophan, a serotonin precursor) may produce additive appetite reduction; monitor caloric adequacy.

  • Supplements with additive metabolic effects: Berberine, alpha-lipoic acid, chromium, and bitter melon also reduce fasting glucose; combination is unlikely to be problematic but warrants self-monitoring in adults using antidiabetic medications.

  • Other interventions: Bariatric surgery patients, patients on parenteral nutrition, and patients with active inflammatory bowel disease have not been studied; intestinal-absorption assumptions may not hold.

  • Populations to avoid (or use only under medical supervision):

    • Pregnant or breastfeeding adults (no human safety data)
    • Adults with active or historical eating disorders
    • Adults with severe hepatic impairment (Child-Pugh Class C)
    • Adults with eGFR <30 ml/min/1.73 m² (renal function below this threshold; not studied)
    • Adults with body mass index <18.5 kg/m² or recent (≤6 months) unintentional weight loss
    • Children and adolescents (<18 years; no pediatric data)

Risk Mitigation Strategies

  • Conservative dose initiation: Begin with 125 mg/day for 1–2 weeks before increasing to the typical 250 mg/day. This addresses the gastrointestinal-discomfort risk and the unintended-weight-loss risk in adults uncertain of their tolerance.

  • Take with a fat-containing meal: Dosing 15–30 minutes before or with a meal that contains some dietary fat optimizes absorption (oleoylethanolamide is a lipid) and aligns with the molecule’s natural postprandial signaling, mitigating gastrointestinal discomfort and reduced bioavailability.

  • Self-monitor blood glucose during early supplementation when on antidiabetic therapy: Adults using sulfonylureas, insulin, or GLP-1 receptor agonists should check fasting and pre-meal glucose more frequently for the first 4 weeks (e.g., daily for the first week, then 2–3 times weekly through week 4) to mitigate the additive hypoglycemia risk. Coordinate any dose adjustments with the prescribing clinician.

  • Track body weight and waist circumference weekly for the first 8 weeks: This is the simplest way to detect unintended weight loss in adults who are not overweight, mitigating the unintended-weight-loss risk.

  • Split dosing across the day: 125 mg with breakfast and 125 mg with dinner is the most common trial protocol and provides more even satiety signaling, mitigating gastrointestinal discomfort that can accompany a single 250 mg dose.

  • Avoid late-evening dosing if sleep is affected: If sleep disturbance occurs, shift the second dose to lunch rather than dinner to mitigate the sleep-disturbance risk.

  • Discontinue and seek clinical review for warning signs: Persistent headache, significant unintended weight loss (>2% body weight in adults not seeking weight loss), persistent gastrointestinal symptoms, or symptoms of hypoglycemia warrant discontinuation and a clinician visit.

  • Re-evaluate every 12 weeks: Periodic reassessment of body weight, lipids, glucose, and inflammatory markers mitigates the risk of indefinite supplementation without measurable benefit, especially given the absence of long-term safety data beyond 15 weeks.

Therapeutic Protocol

A standard practitioner-aligned protocol synthesized from the trials in the 2025 meta-analyses, supplemented with notes on edge cases.

  • Standard dose: 250 mg/day total, taken as 125 mg with breakfast and 125 mg with the evening meal. This is the most frequently studied protocol, used in trials by Tutunchi, Payahoo, Laleh, Ostadrahimi, and colleagues, as well as the Abdullah Gulf War Illness trial (200 mg twice daily ≈ similar exposure).

  • Lower-dose protocol: 125 mg/day total has been used (e.g., Shivyari et al., 2024 in PCOS) and produces measurable effects; this is a reasonable starting dose for adults sensitive to gastrointestinal effects or new to supplementation.

  • Higher-dose investigational protocol: Sabahi et al. (2022) used 300 mg/day or 600 mg/day for 3 days as a stroke-recovery add-on; Rhodes et al. (2024) used escalating doses up to 100 mg/day in fasting-mimetic combination. Sustained dosing above 250 mg/day has not been validated in long-term trials.

  • Best time of day: Take 15–30 minutes before, or together with, the first meal of the day; if split-dosed, the second dose with the largest evening meal. The rationale is to align supplementation with the postprandial physiological window when oleoylethanolamide normally peaks.

  • Half-life and pharmacokinetics: Oleoylethanolamide is rapidly hydrolyzed by FAAH and NAAA; a formal plasma half-life in humans has not been published, but pharmacokinetic work (Rhodes et al., 2024) shows oral oleoylethanolamide produces measurable plasma elevations within 1–4 hours, supporting twice-daily dosing for sustained tone. Investigational LipiSperse-formulated oleoylethanolamide (NCT06840080) is in Phase 4 study to characterize human pharmacokinetics formally.

  • Single vs. split dosing: Twice-daily 125 mg dosing is the dominant protocol in clinical trials and is preferred for sustained signaling. Single 250 mg dosing has been used and is acceptable when adherence to twice-daily is difficult, though it may increase gastrointestinal-discomfort frequency.

  • Genetic polymorphism considerations: No validated pharmacogenomic dosing rules exist. Adults with known FAAH C385A variants (slower clearance) might consider starting at 125 mg/day; adults with PPARA L162V variants might be less responsive but have no specific dose adjustment available.

  • Sex-based differences: No sex-specific dosing recommendations exist. Female-only PCOS and dysmenorrhea trials used 125 mg/day with measurable effects; mixed-sex obesity trials used 250 mg/day.

  • Age-related considerations: Trials have predominantly enrolled adults aged 20–60. Older adults (>65) without sarcopenia and without unintended weight loss can use the standard 250 mg/day protocol; those with sarcopenia or low BMI should consider 125 mg/day with weekly weight monitoring.

  • Baseline biomarkers: Highest expected response in adults with elevated CRP, TNF-alpha, fasting glucose, insulin, HOMA-IR, triglycerides, or central adiposity. Pre-supplementation lipid panel, fasting glucose, fasting insulin, hs-CRP, and ALT/AST establish reference points.

  • Pre-existing conditions: In NAFLD and metabolic syndrome, oleoylethanolamide has been studied as an adjunct to calorie restriction, not as a standalone therapy. In PCOS, the 125 mg/day dose is supported by RCT evidence. In Gulf War Illness, 400 mg/day (200 mg twice daily) was used. None of these are FDA-approved indications.

Discontinuation & Cycling

  • Duration of use: Trials have run 6–15 weeks. Indefinite use is not supported by formal safety data, although oleoylethanolamide is endogenous and FDA has acknowledged it as a New Dietary Ingredient. A reasonable practitioner approach is 8–12 weeks with biomarker re-evaluation, then a decision point on continuation.

  • Withdrawal effects: No withdrawal syndrome has been reported in any published trial. Appetite, body weight, and metabolic markers gradually return toward baseline after cessation.

  • Tapering protocol: None required. Oleoylethanolamide can be discontinued abruptly without adverse effects.

  • Cycling: No formal cycling protocol has been validated. Some practitioners use 12 weeks on followed by a 4-week break to reassess whether continued supplementation is providing measurable benefit relative to lifestyle factors alone; this is empirical and not supported by direct comparative trials.

Sourcing and Quality

  • FDA-acknowledged ingredient: RiduZone (NutriForward LLC, ≈90% oleoylethanolamide) is the original FDA-acknowledged New Dietary Ingredient (2015) and remains the most-studied commercial form in clinical trials.

  • Third-party testing and certification: The oleoylethanolamide market is less mature than that of established supplements, and few products carry NSF International (a third-party testing organization) or USP (United States Pharmacopeia) certification. Look for products that publish a Certificate of Analysis confirming purity (>95% for synthetic preparations) and testing for heavy metals and residual solvents.

  • Reputable brands: RiduZone (NutriForward LLC), California Gold Nutrition Oleoylethanolamide (125 mg capsules, available through major retailers), Synchronicity Health OEA, Mimio (proprietary fasting-mimetic blend including oleoylethanolamide). TRPTI is the ingredient form being studied in several Phase 2 trials registered in 2026.

  • Formulation considerations: Oleoylethanolamide is a lipid; capsule formulations dominate. LipiSperse-enhanced delivery (under Phase 4 study, NCT06840080) aims to improve bioavailability. Bulk powder is available through chemical suppliers but lacks supplement-grade purity verification and is not recommended for non-research use.

  • Storage: Store in a cool, dry place away from direct light and heat; as a fatty-acid amide, oleoylethanolamide can oxidize if mishandled. Refrigeration after opening prolongs shelf life of unprotected lipid preparations.

Practical Considerations

  • Time to effect: Appetite-related effects often emerge within days to 1 week. Lipid, glycemic, and inflammatory marker improvements consistently appear after 6–8 weeks of daily use in trials. Body weight and waist circumference changes accumulate over 8–12 weeks. Mood and fatigue improvements in the Gulf War Illness trial emerged over 10–15 weeks.

  • Common pitfalls:
    • Expecting pharmaceutical-magnitude weight loss: Oleoylethanolamide effects are modest relative to GLP-1 receptor agonists; trial participants typically also followed dietary modifications.
    • Empty-stomach dosing: Reduces lipid absorption and bypasses the natural postprandial mechanism.
    • Premature discontinuation: Stopping before 6–8 weeks misses the metabolic-marker improvements that take that long to develop.
    • Confusion with palmitoylethanolamide (PEA): A related N-acylethanolamine with overlapping but distinct biology (pain and immune modulation rather than appetite and metabolism).
    • Assuming all products are equivalent: Purity and excipient quality vary widely; bulk powder is not equivalent to studied formulations.

  • Regulatory status: Classified as a dietary supplement in the United States. RiduZone (NutriForward LLC) received FDA acknowledgment as a New Dietary Ingredient in 2015. Oleoylethanolamide is not FDA-approved as a drug for any medical indication; use for any specific disease state is off-label in the supplement-use sense.

  • Cost and accessibility: RiduZone retails at approximately $40–$50 USD for a one-month supply. California Gold Nutrition oleoylethanolamide is available at approximately $15–$25 USD per 120-capsule bottle. Bulk powder is cheaper but requires sourcing diligence. Availability is widest through specialty supplement retailers and online platforms.

Interaction with Foundational Habits

  • Sleep: No direct sleep-promoting or sleep-disrupting mechanism is established. A subset of users report difficulty initiating sleep when oleoylethanolamide is dosed late, possibly via dopaminergic activation or increased energy metabolism. Direction: indirect, mostly neutral. Practical consideration: if sleep is affected, shift the second dose to lunch; consider whether reductions in systemic inflammation (CRP, TNF-alpha) over 8–12 weeks contribute to subjective sleep-quality improvements indirectly.

  • Nutrition: Oleoylethanolamide is endogenously synthesized from oleic acid, the dominant fatty acid in olive oil and a major fatty acid in avocados, almonds, and high-oleic safflower or sunflower oils. Direction: potentiating relationship — Mediterranean-style diets supply substrate for endogenous synthesis, and supplementation may show smaller incremental effects in adults already eating high-oleic-acid diets. Practical consideration: pair supplementation with meals containing some monounsaturated fat for absorption; oleoylethanolamide does not deplete known nutrients.

  • Exercise: No direct interaction with strength or endurance performance has been formally studied. Direction: potentially potentiating for fat oxidation through PPAR-alpha pathway overlap with exercise-induced fat utilization; appetite suppression could be problematic for high-volume training requiring large caloric intake. Practical consideration: athletes and adults in heavy training blocks should monitor caloric adequacy and lean-mass preservation.

  • Stress management: The Abdullah et al. (2026) Gulf War Illness trial and the PCOS trials suggest oleoylethanolamide may have stress-modulating effects, likely through anti-inflammatory pathways. Direction: indirect potentiating of stress resilience. Practical consideration: oleoylethanolamide is not a primary stress-management tool; foundational practices (sleep, exercise, social connection) remain the principal interventions.

Monitoring Protocol & Defining Success

Baseline laboratory and anthropometric measurements should be established before starting oleoylethanolamide to enable objective tracking of effects.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting glucose 72–85 mg/dl Baseline glycemic control Conventional cutoff <100 mg/dl; fast 10–12 hours
Fasting insulin 2–5 microU/ml Insulin sensitivity at rest Lab reference 2–25 microU/ml; lower is better
HOMA-IR <1.0 Composite insulin-resistance estimate Homeostatic Model Assessment for Insulin Resistance; calculated from fasting glucose and insulin; conventional cutoff <2.5
HbA1c <5.3% Long-term glucose control Glycated hemoglobin; conventional cutoff <5.7%; not expected to change in <8 weeks
hs-CRP <0.5 mg/L Systemic inflammation High-sensitivity C-reactive protein; conventional cutoff <3.0 mg/L; functional optimum is much lower
TNF-alpha Lab-specific Tracks key inflammatory cytokine Tumor necrosis factor-alpha; less commonly available; useful when accessible
Triglycerides <70 mg/dl Lipid response to PPAR-alpha activation Conventional cutoff <150 mg/dl; fasting required
Total cholesterol, LDL-C, HDL-C Individualized Baseline lipid context LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; not expected to change significantly with oleoylethanolamide alone
ALT 7–21 U/L Liver health Alanine aminotransferase; conventional upper limit higher; especially relevant in NAFLD
AST 10–26 U/L Liver health Aspartate aminotransferase; functional optimum tighter than conventional reference
Body weight and waist circumference Individualized Body composition tracking Same time of day, same conditions; waist measured at navel

Ongoing Monitoring

A typical cadence: re-measure body weight weekly for the first 8 weeks, waist circumference every 2 weeks for the first 8 weeks, fasting metabolic panel and hs-CRP at 8–12 weeks, and ALT/AST at 12 weeks if NAFLD is being targeted. Reassess overall response at 12 weeks to decide on continuation, dose adjustment, or discontinuation.

Qualitative Markers

  • Appetite reduction and ease of staying within caloric targets
  • Subjective energy levels and fatigue
  • Mood stability and emotional well-being
  • Gastrointestinal comfort
  • Sleep quality
  • Any unintended weight loss or muscle loss

Emerging Research

Active research is expanding oleoylethanolamide investigation across metabolic, longevity, sleep, and addiction domains.

  • Sleep, stress, and anxiety trial: A Phase 2 RCT comparing lavender oil, palmitoylethanolamide, and oleoylethanolamide (TRPTI) versus placebo over 8 weeks for moderate stress with sleep difficulty: Sleep and Stress Study (NCT07315516, n=240, recruiting).

  • Glucose tolerance dose-response trial: A Phase 2 crossover trial testing TRPTI 150 mg vs 300 mg vs placebo on glucose AUC (area under the curve, a measure of total glucose exposure over time) after a glucose load: Glucose Tolerance Study (NCT07412730, n=20, not yet recruiting).

  • Gut microbiome and imidazole propionate trial: A Phase 2 trial testing whether TRPTI reduces plasma imidazole propionate (a microbiota-derived metabolite linked to insulin resistance): Gut Microbiome and Metabolic Health Study (NCT07457723, n=90, not yet recruiting).

  • Alcohol use disorder trial: A Phase 2 RCT in young adults with alcohol use disorder testing TRPTI 300 mg (250 mg/day oleoylethanolamide) vs placebo for 6 weeks: OEA for Young Adults With Alcohol Use Disorder (NCT07503782, n=42, not yet recruiting).

  • Metabolic and epigenetic gene-expression study: A completed 12-week trial of an oleoylethanolamide/ginger/lavender formulation in healthy adults to characterize gene-expression and protein-marker changes: Metabolic and Epigenetic Impact of FAAH Inhibitors and OEA (NCT07127445, n=92, completed).

  • LipiSperse pharmacokinetic study: A Phase 4 crossover study comparing 125 mg and 250 mg oleoylethanolamide with LipiSperse delivery technology versus placebo: OEA and LipiSperse Metabolic Study (NCT06840080, n=40, completed).

  • Fasting-mimetic combination work: Rhodes et al. (2024) published a pilot dose-escalation study of a four-metabolite fasting-mimetic (spermidine + nicotinamide + palmitoylethanolamide + oleoylethanolamide) in healthy young men, demonstrating bioavailability and dose-dependent anti-inflammatory and cholesterol-efflux effects: Absorption, anti-inflammatory, antioxidant, and cardioprotective impacts of a novel fasting mimetic (Rhodes et al., 2024).

  • Fasting-derived longevity metabolite work: Rhodes et al. (2023) showed that prolonged human fasting upregulates plasma oleoylethanolamide and three other metabolites that, in combination, extend nematode lifespan by up to 96%: Human fasting modulates macrophage function and upregulates multiple bioactive metabolites that extend lifespan in Caenorhabditis elegans (Rhodes et al., 2023).

  • Sex-specific endocannabinoid response: Abboud et al. (2026) reported sex-specific changes in plasma oleoylethanolamide after low-dose oral cannabidiol, raising questions about sex-modulated tone in oleoylethanolamide-network interventions: Sex-specific association between low oral doses of cannabidiol and plasma concentration of anandamide, palmitoylethanolamide and oleoylethanolamide (Abboud et al., 2026).

  • Research areas that could weaken the case: Independent replication outside the Tabriz/Iran research cluster has been slow; recent work by the Rhodes group at UC Davis (Rhodes et al., 2023; Rhodes et al., 2024) and the Abdullah Gulf War Illness trial begin to fill this gap. Trials in normal-weight adults are absent. No trial has examined long-term outcomes (cardiovascular events, cancer incidence, mortality), and a formal human pharmacokinetic and tissue-distribution profile is still pending.

  • Research areas that could strengthen the case: Multi-center RCTs in metabolic syndrome with extended follow-up, head-to-head comparisons against established interventions (Mediterranean diet, GLP-1 receptor agonists), pharmacogenomic substudies in PPARA and FAAH variants per the systematic-review groundwork (Tutunchi et al., 2020), and direct longevity-aligned biomarker work (epigenetic age, immune-cell function) would clarify whether oleoylethanolamide deserves a place in longevity protocols beyond its current metabolic-support role.

Conclusion

Oleoylethanolamide is a body-derived signaling lipid that the small intestine releases after fat-containing meals, where it activates a fat-burning nuclear receptor and stimulates vagus-nerve fibers carrying a “fullness” signal to the brain. Pooled analyses of randomized clinical trials show that adults taking oleoylethanolamide for several weeks see consistent reductions in body weight, waist circumference, fasting glucose, insulin resistance, triglycerides, and inflammatory markers, alongside small improvements in antioxidant capacity. Magnitudes are modest rather than transformative, and effects cluster in adults who start with elevated metabolic and inflammatory markers.

The safety record across published trials is reassuring: no serious adverse events have been reported, and animal toxicity studies show wide margins. The most common complaints are mild and transient, mostly digestive. Important caveats remain. Most trials are small, short, and concentrated in one research cluster — a structural-bias caveat that warrants caution about effect sizes. Long-term outcomes are unstudied. None of the major longevity-oriented physicians and researchers commonly followed by this audience have publicly endorsed oleoylethanolamide, reflecting its emerging rather than established status. Effects on long-term blood-sugar averages and on cholesterol fractions other than triglycerides are not significant.

For adults with elevated metabolic or inflammatory markers, the evidence shows a coherent metabolic and anti-inflammatory signal of modest magnitude, set against a small, geographically concentrated trial base and an absence of long-term outcome data.

Top - Benefits - Risks - Protocol